Methazolamide: Difference between revisions
m (Protected "Methazolamide": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| Line 27: | Line 27: | ||
{{SI}} | {{SI}} | ||
'''Methazolamide (Neptazane®)''' is a [[carbonic anhydrase]] inhibitor. | '''Methazolamide (Neptazane®)''' is a [[carbonic anhydrase]] inhibitor. | ||
| Line 38: | Line 38: | ||
{{Antiglaucoma preparations and miotics}} | {{Antiglaucoma preparations and miotics}} | ||
[[Category:Carbonic anhydrase inhibitors]] | [[Category:Carbonic anhydrase inhibitors]] | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 17:22, 9 August 2012
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 55% |
| Elimination half-life | 14 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C5H8N4O3S2 |
| Molar mass | 236.274 g/mol |
|
WikiDoc Resources for Methazolamide |
|
Articles |
|---|
|
Most recent articles on Methazolamide Most cited articles on Methazolamide |
|
Media |
|
Powerpoint slides on Methazolamide |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Methazolamide at Clinical Trials.gov Trial results on Methazolamide Clinical Trials on Methazolamide at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Methazolamide NICE Guidance on Methazolamide
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Methazolamide Discussion groups on Methazolamide Patient Handouts on Methazolamide Directions to Hospitals Treating Methazolamide Risk calculators and risk factors for Methazolamide
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Methazolamide |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Methazolamide (Neptazane®) is a carbonic anhydrase inhibitor.
References
- Iyer G, Bellantone R, Taft D (1999). "In vitro characterization of the erythrocyte distribution of methazolamide: a model of erythrocyte transport and binding kinetics". J Pharmacokinet Biopharm. 27 (1): 45–66. PMID 10533697.
- RxList. "Neptazane". Unknown parameter
|accessyear=ignored (|access-date=suggested) (help); Unknown parameter|accessmonthday=ignored (help) - Shirato S, Kagaya F, Suzuki Y, Joukou S (1997). "Stevens-Johnson syndrome induced by methazolamide treatment". Arch Ophthalmol. 115 (4): 550–3. PMID 9109770.
- Skorobohach B, Ward D, Hendrix D (2003). "Effects of oral administration of methazolamide on intraocular pressure and aqueous humor flow rate in clinically normal dogs". Am J Vet Res. 64 (2): 183–7. PMID 12602587.
Template:Antiglaucoma preparations and miotics Template:WH Template:WikiDoc Sources
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- CS1 maint: Multiple names: authors list
- Pages with citations using unsupported parameters
- Carbonic anhydrase inhibitors